Oxford BioMedica (OXBDF) Price & Analysis
OXBDF Stock Chart & Stats
- Day’s Range
- $7.02 - $7.60
- 52-Week Range
- $5.80 - $13.15
- Previous Close
- $7.10
- Volume
- 100
- Average Volume (3M)
- 609
- Market Cap
- $873.87M
- Enterprise Value
- $838.44M
- Total Cash (Recent Filing)
- $75.28M
- Total Debt (Recent Filing)
- $158.64M
- Price to Earnings (P/E)
- ―
- Beta
- 0.24
- Next Earnings
- Apr 15, 2027
- EPS Estimate
- -0.03
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving Revenue Growth
The return to meaningful revenue growth indicates improving demand for Oxford BioMedica’s viral-vector development and manufacturing services. If sustained, stronger activity can support better capacity utilization, deepen partner relationships, and provide a foundation for future operating leverage.
Solid Gross Margin
A consistently solid gross margin suggests the CDMO model can retain meaningful value from its specialized development and GMP manufacturing work. Maintaining this margin profile would help the company convert future revenue growth into improved earnings as scale and utilization increase.
Improving Leverage
Lower debt relative to equity represents a measurable improvement in balance-sheet resilience and reduces leverage pressure compared with the prior year. Greater equity support can provide more flexibility to fund development and manufacturing activities while the business works toward profitability.
Bears Say
Persistent Unprofitability
Continued operating and net losses show that revenue growth has not yet translated into sustainable earnings power. Persistent unprofitability can limit internally funded investment, weaken financial flexibility, and make execution on the company’s growth strategy more dependent on external support.
Negative Cash Generation
Negative operating and free cash flow indicate that current operations are not yet funding the company’s investment needs. Although outflows improved sharply from 2024, ongoing cash consumption can constrain expansion, require additional funding, and remain a durable risk until profitability improves.
Meaningful Debt And Negative Returns
The company still carries a meaningful debt burden while generating negative returns on equity, showing that invested capital has not yet produced profitable returns. This combination can restrict capital-allocation flexibility and increase the importance of achieving durable earnings and cash-flow improvement.
Oxford BioMedica News
OXBDF FAQ
What was Oxford BioMedica’s price range in the past 12 months?
What is Oxford BioMedica’s market cap?
When is Oxford BioMedica’s upcoming earnings report date?
How were Oxford BioMedica’s earnings last quarter?
Is Oxford BioMedica overvalued?
Does Oxford BioMedica pay dividends?
What is Oxford BioMedica’s EPS estimate?
How many shares outstanding does Oxford BioMedica have?
What happened to Oxford BioMedica’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Oxford BioMedica?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Oxford BioMedica
Oxford Biomedica plc is a biopharmaceutical firm focused on the discovery, advancement, and sophisticated bioprocessing of innovative cell and gene therapies. Operating globally, with a strong presence across Europe, the company organizes its activities into two segments: Platform and Product. Its proprietary LentiVector platform technology facilitates the integration of genes into non-dividing cells, such as neurological cells in the brain and retinal cells in the eye, and can incorporate diverse therapeutic genes. The company's developmental pipeline includes promising candidates like Axo-Lenti-PD, a gene-based treatment for Parkinson's disease. Other pre-clinical stage programs feature OXB-302, targeting haematological tumors, and OXB-401, OXB-40X, and OXB-40Y, all addressing liver indications. Oxford Biomedica maintains numerous strategic alliances with prominent pharmaceutical entities such as Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and the Vaccines Manufacturing and Innovation Centre. Additionally, it engages in research collaborations, including a partnership with Circularis Biotechnologies to identify novel tissue-specific promoters for in vivo lentiviral gene therapy, Virica Biotech for scaling viral medicines, Isolere Bio for enhancing downstream manufacturing efficiencies of biologics, and BiologIC Technologies for utilizing a novel biocomputer system in viral vector development. Founded in 1995, Oxford Biomedica plc is headquartered in Oxford, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Frank Mathias
- Employees
- 1,017
- Website
- www.oxb.com
- Address
- Windrush Court, Oxford, OXF, OX4 6LT, GB
Oxford BioMedica (OXBDF) Earnings & Revenues
OXBDF Company Deck
OXBDF Earnings Call
Earnings Call SentimentPositive
The earnings call presented a positive outlook with significant revenue growth, increased client orders, operational efficiency improvements, and strategic expansions. However, challenges such as the operating EBITDA loss and negative working capital movement were noted.
View all OXBDF earnings summariesOXBDF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 4 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 9 | 0 | 3 |